Browsing Category
Pharma Industry News
4741 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
Pfizer to buy Metsera in $7.3bn obesity drug deal, challenging Lilly and Novo
Pfizer’s $7.3B Metsera takeover could reshape the GLP-1 obesity drug race and challenge Eli Lilly and Novo Nordisk’s dominance in weight loss treatments.
Rubicon Research Rs 140cr pre-IPO boost: Can the pharma firm deliver sustained growth?
Rubicon Research secures â‚ą140 crore from TIMF Holdings and 360 ONE Funds ahead of IPO. Find out how the pharma player is positioning for growth.
AusperBio raises $63mn series B2 round to advance AHB-137 and expand global hepatitis B
AusperBio raises $63M Series B2 funding to advance AHB-137 pivotal trials, expand its Med-Oligo platform, and reshape the hepatitis B cure race.
Ipsen stock edges higher as Japan clears Bylvay for rare liver disease — is the upside real for investors?
Ipsen (IPN) gains after Japan approves Bylvay for rare liver disease. See stock performance, analyst sentiment, and whether it’s time to buy, hold, or sell.
Genfit abandons VS-01 in ACLF after safety scare—can a pivot to UCD rescue GNFT’s pipeline story?
Genfit ends VS-01 in ACLF and refocuses on UCD, trims spend, and extends runway beyond 2028. Find out what it means for GNFT stock and 2025 catalysts.
Jyong Biotech stock surges 26.8% as Phase II prostate cancer trial enrollment milestone boosts investor confidence
Jyong Biotech (NASDAQ: MENS) stock jumped 26.8% after completing enrollment of 700 patients in its Phase II prostate cancer prevention trial MCS-8.
Can Merck’s new Keytruda injection delay biosimilar threats and change cancer care forever?
Find out how Merck’s newly FDA-approved Keytruda QLEX injectable version aims to improve cancer care with faster, more convenient treatment. Read on.
DryEye Rescue launches Rescue Link to transform OTC eye care product recommendations for providers
Discover how DryEye Rescue’s new Rescue Link platform helps eye care providers boost patient compliance and drive revenue through personalized product links.
Can Johnson & Johnson’s TECVAYLI and DARZALEX FASPRO regimen redefine first-line multiple myeloma treatment?
Johnson & Johnson’s TECVAYLI + DARZALEX FASPRO combo hit 100% MRD negativity in new myeloma trial. Can this immune-based regimen redefine frontline care?
KalVista Pharmaceuticals wins EU and Swiss approval for EKTERLY—what does this mean for the stock?
KalVista Pharmaceuticals secures EU and Swiss approval for EKTERLY, the first oral HAE therapy. Can this rare disease breakthrough lift KALV stock?